Jan 27, 2025 · Invivyd creates medicines that are more potent and resistant to virus evolution than the human immune system. We deploy a proprietary integrated technology platform unique in the industry to assess, monitor, develop, and adapt to create best in class antibodies.

4 days ago · Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies.

4 days ago · Primarily driven by a reduction of manufacturing expenses, Invivyd is also announcing preliminary Q4 2024 total operating costs and expenses of approximately $32 million, representing a 55% ...

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.

Invivyd Inc (NASDAQ:IVVD) is a biopharma company that makes antibody-based treatments. The primary target is COVID-19. The stock has surged significantly so far in 2025 due to Q4 2024 net product ...

Jan 27, 2025 · Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.

Jan 10, 2025 · Invivyd has demonstrated positive PEMGARDA neutralization activity against over 75% of currently circulating U.S. variants, and all prior variants, tested to date.

Invivyd is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases.

May 31, 2024 · Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. The company’s proprietary INVYMAB™ platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering.

2 days ago · Invivyd, Inc.’s price is currently up 249.45% so far this month. During the month of February, Invivyd, Inc.’s stock price has reached a high of $1.430 and a low of $0.436. Over the last year, Invivyd, Inc. has hit prices as high as $5.100 and as low as $0.355. Year to date, Invivyd, Inc.’s stock is up 182.1%.